Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116995 | 1.00 | CTSK (0.51) | CTSKCTSSAPPGABRB1GABRB2 | |
| SCHEMBL14250689 | 1.00 | CTSK (0.51) | CTSKCTSSAPPGABRB1GABRB2 | |
| SCHEMBL3379781 | 1.00 | CTSK (0.51) | CTSKCTSSAPPGABRB1GABRB2 | |
| SCHEMBL3414715 | 1.00 | CTSK (0.51) | CTSKCTSSAPPGABRB1GABRB2 | |
| SCHEMBL7857496 | 0.92 | CTSK (0.48) | CTSKCTSSAPPPPARAPPARG | |
| SCHEMBL4686608 | 0.88 | CTSK (0.49) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL4686602 | 0.88 | CTSK (0.49) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL3375608 | 0.88 | CTSK (0.49) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL2573117 | 0.88 | CTSK (0.45) | CTSKCTSSAPPPPARAPPARG | |
| SCHEMBL1241183 | 0.87 | CTSK (0.41) | CTSKCTSSAPPPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262026-B1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-18 | — | — | EP | disclosed |
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-9980929-B2 | Trifluoromethylpropanamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9422332-B2 | Azaheterocycles as BIR2 and/or BIR3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-9260427-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2621508-B1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | SEATTLE GENETICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | NIU HUIFENG | 2008-08-28 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
| WO-2007091018-A1 | NON-NATURAL AMINO ACID DERIVATIVES | PROXIMAGEN LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| EP-1781649-A2 | SUBSTITUTED HYDANTOINS | F. Hoffmann-Roche AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
| WO-2006018188-A2 | SUBSTITUTED HYDANTOINS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSK 3229/4885CTSS 3233/4885APP 783/4885 |
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | CTSK 1484/4885CTSS 1187/4885APP 1517/4885 |
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | PRMT7, GFRA3, PRMT5 | CTSK 2343/4885CTSS 1843/4885APP 1799/4885 |
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSK 1629/4885CTSS 1158/4885APP 2847/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | CTSK 1706/4885CTSS 2162/4885APP 3905/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | CTSK 964/4885CTSS 1444/4885APP 4577/4885 |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | MKI67, BRAF, MYC | CTSK 1094/4885CTSS 1869/4885APP 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.